Correct growth but a cautious view is still advisable
- During Q4 2015, SIPHAT recorded a modest growth in sales (+2.7%) compared to Q4 2014, going from TND11.9M to TND12.5M. This progression has been pulled up by the rise in the quarterly revenues of the hospital model to TND6.05M (+23.8%). The production value reached TND12.02M, up from TND11.06M in the same period of 2015. Thus, the company ended the year 2015 with an 8% sales increase to TND44.455M, a trend that outperformed our projections (+2.7% expected by AlphaMena).
AlphaMena is the MENA stocks leader in independent equity research, covering 142. MENA securities spanning across 19 sectors and 8 countries relaying on a team of 11 analysts. The breadth of coverage allows AlphaMena to formulate a coherent view on markets, sectors and to highlight the best investments in Mena zone using a robust homogeneous and transparent methodology, enabling pure and pertinent comparisons based on financial and extra-financial criteria.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.